1. Absalom AR, Glen JI, Zwart GJ, Schnider TW, Struys MM. Target-controlled infusion: a mature technology. Anesth Analg. 2016; 122:70–78. PMID:
26516798.
2. Marsh B, White M, Morton N, Kenny GN. Pharmacokinetic model driven infusion of propofol in children. Br J Anaesth. 1991; 67:41–48. PMID:
1859758.
3. Struys MM, De Smet T, Depoorter B, Versichelen LF, Mortier EP, Dumortier FJ, et al. Comparison of plasma compartment versus two methods for effect compartment-controlled target-controlled infusion for propofol. Anesthesiology. 2000; 92:399–406. PMID:
10691226.
4. Schnider TW, Minto CF, Gambus PL, Andresen C, Goodale DB, Shafer SL, et al. The influence of method of administration and covariates on the pharmacokinetics of propofol in adult volunteers. Anesthesiology. 1998; 88:1170–1182. PMID:
9605675.
5. Schnider TW, Minto CF, Shafer SL, Gambus PL, Andresen C, Goodale DB, et al. The influence of age on propofol pharmacodynamics. Anesthesiology. 1999; 90:1502–1516. PMID:
10360845.
6. Lee SH, Park HW, Kim MJ, Noh MH, Yoon HS, Choi BM, et al. External validation of pharmacokinetic and pharmacodynamic models of microemulsion and long-chain triglyceride emulsion propofol in beagle dogs. J Vet Pharmacol Ther. 2012; 35:329–341. PMID:
21790660.
8. Vaisman N, Dotan I, Halack A, Niv E. Malabsorption is a major contributor to underweight in Crohn's disease patients in remission. Nutrition. 2006; 22:855–859. PMID:
16928471.
9. Rigaud D, Angel LA, Cerf M, Carduner MJ, Melchior JC, Sautier C, et al. Mechanisms of decreased food intake during weight loss in adult Crohn's disease patients without obvious malabsorption. Am J Clin Nutr. 1994; 60:775–781. PMID:
7942586.
10. Gepts E, Camu F, Cockshott ID, Douglas EJ. Disposition of propofol administered as constant rate intravenous infusions in humans. Anesth Analg. 1987; 66:1256–1263. PMID:
3500657.
11. Minto CF, Schnider TW, Egan TD, Youngs E, Lemmens HJ, Gambus PL, et al. Influence of age and gender on the pharmacokinetics and pharmacodynamics of development. Anesthesiology. 1997; 86:10–23. PMID:
9009935.
12. Glen JB, Servin F. Evaluation of the predictive performance of four pharmacokinetic models for propofol. Br J Anaesth. 2009; 102:626–632. PMID:
19297371.
13. Coetzee JF, Glen JB, Wium CA, Boshoff L. Pharmacokinetic model selection for target controlled infusions of propofol. Assessment of three parameter sets. Anesthesiology. 1995; 82:1328–1345. PMID:
7793646.
14. Vereecke HE, Eleveld DJ, Colin P, Struys MM. Performance of the Eleveld pharmacokinetic model to titrate propofol in an obese Japanese patient population. Eur J Anaesthesiol. 2016; 33:58–59. PMID:
26086291.
15. Best WR, Becktel JM, Singleton JW, Kern F Jr. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology. 1976; 70:439–444. PMID:
1248701.
16. Kim KM, Choi BM, Park SW, Lee SH, Christensen LV, Zhou J, et al. Pharmacokinetics and pharmacodynamics of propofol microemulsion and lipid emulsion after an intravenous bolus and variable rate infusion. Anesthesiology. 2007; 106:924–934. PMID:
17457123.
17. Bouillon TW, Bruhn J, Radulescu L, Andresen C, Shafer TJ, Cohane C, et al. Pharmacodynamic interaction between propofol and remifentanil regarding hypnosis, tolerance of laryngoscopy, bispectral index, and electroencephalographic approximate entropy. Anesthesiology. 2004; 100:1353–1372. PMID:
15166553.